Clinical trial
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
NCT00019435 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019435 |
|---|---|
| Title | LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Immunotoxin for Advanced Carcinomas That Express Lewis Y Antigen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | LMB-9 immunotoxin |
| Start date | May 1, 1998 |
| First posted | May 6, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: